Shareholders approved a 16-for-1 reverse stock split of Class A and Class B ordinary shares, effective October 6, 2026. The consolidation reduces outstanding Class A shares from approximately 109.4 million to roughly 6.8 million and Class B shares from 7.7 million to roughly 479 thousand. Authorized share capital will increase from US$50,000 to US$800,000. The move aims to meet Nasdaq's $1.00 minimum bid price requirement by the October 19 deadline. iTonic Holdings Ltd operates in the healthcare technology industry, developing digital medical solutions and intelligent data platforms.
